Abemaciclib (Standard)

CAT: 0804-HY-16297AR-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-16297AR-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Abemaciclib (Standard) is the analytical standard of Abemaciclib. This product is intended for research and analytical applications. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
CAS Number
[1231929-97-7]
Product Name Alternative
LY2835219 (Standard)
UNSPSC
12352005
Hazard Statement
H360, H373, H410
Target
CDK; Reference Standards
Type
Reference Standards
Related Pathways
Cell Cycle/DNA Damage; Others
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/abemaciclib-standard.html
Purity
99.94
Smiles
CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C
Molecular Formula
C27H32F2N8
Molecular Weight
506.59
Precautions
H360, H373, H410
References & Citations
[1]Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget.?2016 Mar 22;7 (12) :14803-13.|[2]Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13 (10) :2253-63.|[3]Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32 (5) :825-37.
Shipping Conditions
Blue Ice
Storage Conditions
4°C, sealed storage, away from light and moisture
Scientific Category
Reference Standards

Popular Products